Appetite stimulants use in cystic fibrosis

Pediatric Pulmonology

Volumn 43, Issue 3, 2008, Pages 209-219

  Nasr, Samya Z ^a   Drury, Donna ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b MONTREAL CHILDREN S HOSPITAL   (Canada)

Author keywords

Anabolic androgenic steroids; Antidepressants; Antipsychotic drugs; Appetite stimulants; Cyproheptadine hydrochloride; Cystic fibrosis; Dronabinol; Megestrol acetate; Recombinant human growth hormone

Indexed keywords

CLOZAPINE; CYPROHEPTADINE; DRONABINOL; HUMAN GROWTH HORMONE; MEGESTROL ACETATE; MIRTAZAPINE; OLANZAPINE; OXANDROLONE; PLACEBO; PREDNISONE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ACROMEGALY; ADRENAL SUPPRESSION; ALCOHOL LIVER DISEASE; ALOPECIA; ANOREXIA; ANXIETY; ARTHRALGIA; BREAST CANCER; CALORIC INTAKE; CARPAL TUNNEL SYNDROME; CATARACT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CYSTIC FIBROSIS; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSLIPIDEMIA; EDEMA; EPIPHYSIS; EUPHORIA; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL TOXICITY; GLUCOSE INTOLERANCE; GLUCOSURIA; GROWTH RETARDATION; GROWTH, DEVELOPMENT AND AGING; GYNECOMASTIA; HIRSUTISM; HUMAN; HYPERACTIVITY; HYPERGLYCEMIA; INCREASED APPETITE; INSOMNIA; INSULIN RESISTANCE; IRRITABILITY; LEUKEMIA; LIVER DYSFUNCTION; LONG TERM CARE; LOW DRUG DOSE; LUNG FUNCTION; MALNUTRITION; NUTRITIONAL STATUS; OSTEOPOROSIS; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEDATION; SHORT STATURE; SIDE EFFECT; SOMNOLENCE; SURVIVAL; THIRST; TREATMENT DURATION; TREATMENT FAILURE; TURNER SYNDROME; WASTING SYNDROME; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; APPETITE STIMULANTS; CHILD; CHILD NUTRITION DISORDERS; CHILD, PRESCHOOL; CYSTIC FIBROSIS; HUMAN DEVELOPMENT; HUMAN GROWTH HORMONE; HUMANS; INFANT; NUTRITION ASSESSMENT;

EID: 40649098267     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.20766     Document Type: Review

References (102)

1. Peterson ML, Jacobs DR, Milla CE. Longitudinal changes in growth parameters are correlated with changes in pulmonary function in children with cystic fibrosis. Pediatrics 2003;112: 588-592.
2. Konstan MW, Butler SM, Wohl ME, Stoddard M, Matousek R, Wagener JS, Johnson CA, Morgan WJ. Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis. J Pediatr 2003; 142: 624-630.
3. Hart N, Tounian P, Clément A, Boulé M, Polkey MI, Lofaso F, Fauroux B. Nutritional status is an important predictor of diaphragm strength in young patients with cystic fibrosis. Am J Clin Nutr 2004;80:1201-1206.
4. Sharma R, Florea VG, Bolger AP, Doehner W, Florea ND, Coats AJ, Hodson ME, Anker SD, Henein MY. Wasting as an independent predictor of mortality in patients with cystic fibrosis. Thorax 2001;56:746-750.
5. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation, patient registry 2003. Bethesda, MD: Cystic Fibrosis Foundation; 2004.
6. Druce M, Bloom SR. The regulation of appetite. Arch Dis Child 2006;91:183-187.
7. Small CJ, Bloom SR. Gut hormones and the control of appetite. Trends Endocrinol Metab 2004;15:259-263.
8. Blundell JE, Lawton CL, Cotton JR, Macdiarmid JI. Control of human appetite: implications for the intake of dietary fat. Ann Rev Nutrition 1996;16:285-319.
9. Misra M, Miller KK, Almazan C, Ramaswamy K, Aggarwal A, Herzog DB, Neubauer G, Breu J, Klibanski A. Hormonal and body composition predictors of soluble leptin receptor, leptin, and free leptin index in adolescent girls with anorexia nervosa and controls and relation to insulin sensitivity. J Clin Endocrinol Metab 2004;89:3486-3495.
10. Alexieva-Figusch J, van Gilse HA, Hop WCJ. Progestin therapy in advanced breast cancer. Megestrol acetate-an evaluation of 160 treated cases. Cancer 1980;46:2369-2372.
11. Strang P. The effect of megestrol acetate on anorexia, weight loss and cachexia in cancer and AIDS patients. Anticanc Res 1997; 17:657-662.
12. McCarthy H, Crowder R, Dryden S, Williams G. Megestrol acetate stimulates food and water intake in the rat: effects on regional hypothalamic neuropeptide Y concentrations. Eur J Pharmacol 1994;265:99-102.
13. Aisner J, Parnes H, Tait N, Hickman M, Forrest A, Greco FA, Tchekmedyian NS. Appetite stimulation and weight gain with megestrol acetate. Semin Oncol 1990;17:2-7.
14. Loprinzi CL, Johnson PA, Jensen M. Megestrol acetate for anorexia and cachexia. Oncology 1992;49:46-49.
15. Tchekmedyian NS, Hickman M, Heber D. Treatment of anorexia and weight loss with megestrol acetate in patients with cancer or acquired immunodeficiency syndrome. Semin Oncol 1991;18: 35-42.
16. Feliu J, Gonzelez-Baron M, Berrocal A. Usefulness of megestrol acetate in cancer cachexia and anorexia: a placebo-controlled study. Am J Clin Oncol 1992;15:436-440.
17. Loprinzi CL, Ellison NM, Schaid DJ, Krook JE, Athmann LM, Dose AM, Mailliard JA, Johnson PS, Ebben LP, Geeraerts LH. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Nat Cane Inst 1990; 82:1127-1132.
18. Gebbia V, Testa A, Gebbia N. Prospective randomized trial of two dose levels of megestrol acetate in the management of anorexia-cachexia syndrome in patients with metastatic cancer. Br J Canc 1996;73:1576-1580.
19. Oster MH, Enders SR, Samuels SJ, Cone LA, Hooton TM, Browder HP, Flynn NM. Megestrol acetate in patients with AIDS and cachexia. Ann Intern Med 1994;121:400-408.
20. Von Roenn JH, Armstrong D, Kotier DP, Cohn DL, Klimas NG, Tchekmedyian NS, Cone L, Brennan PJ, Weitzman SA. Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med 1994;121:393-399.
21. Westman G, Bergman B, Albertsson M, Kadar L, Gustavsson G, Thanning L, Andersson M, Straumits A, Jeppson B, Lindén CJ, Ewers SB, Andersson H, Mercke C, Hafström L, Birck O, Orgum P. Megestrol acetate in advanced progressive hormone-insensitive cancer. Effects on the quality of life: a placebo-controlled, randomised multicentre trial. Eur J Cancer 1999;35:586-595.
22. Tomiska M, Tomiskova M, Salajka F, Adam Z, Vorlicek J. Palliative treatment of cancer anorexia with oral suspension of megestrol acetate. Neoplasma 2003;50:227-233.
23. Nasr SZ, Hurwitz ME, Brown RW, Elghoroury M, Rosen D. Treatment of anorexia and weight loss with megestrol acetate in patients with cystic fibrosis. Pediatr Pulmonol 1999;28:380-382.
24. Marchand V, Baker SS, Stark TJ, Baker RD. Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. J Pediatr Gastroenterol Nutr 2000;31:264-269.
25. Eubanks V, Koppersmith N, Wooldridge N, Clancy JP, Lyrene R, Arani RB, Lee J, Moldawer L, Atchison J, Sorscher EJ, Makris CM. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. J Pediatr 2002;140:439-444.
26. Kawachak DA, Zhao H, Scanlin TF, Tomezsko JL, Cnaan A, Stallings VA. Longitudinal, prospective analysis of dietary intake in children with cystic fibrosis. J Pediatr 1996;129:119-129.
27. Schmoll E, Wilke H, Thole R, Preusser P, Wildfang I, Schmoll HJ. Megestrol acetate in cancer cachexia. Semin Oncol 1991;18:32-34.
28. Wermers RA, Hurley DL, Kearns AE. Osteoporosis associated with megesterol acetate. Mayo Clin Proc 2004;79:1557-1561.
29. Bergen SS. Appetite stimulating properties of cyproheptadine. Am J Dis Child 1964;108:270-273.
30. Steil JN, Liddle GW, Lacy WW. Studies of mechanism of cyproheptadine-induced weight gain in human subjects. Metabolism 1970;19:192-200.
31. Noble RE. Effect of cyproheptadine on appetite and weight gain in adults. JAMA 1999;209:2054-2056.
32. Lavenstein AF, Dacaney EP, Lasagna L, Van Metre TE. Effect of cyproheptadine on asthmatic children. JAMA 1962;180:912-916.
33. Goldberg SC, Halmi KA, Eckert ED, Casper RC, Davis JM. Cyproheptadine in anorexia nervosa. Br J Psychiatry 1979;134:67-70.
34. Rahman KM. Appetite stimulation and weight gain with cyproheptadine (Periactin) in tuberculosis patients (double-blind clinical study). Med J Malaysia 1975;29:270-274.
35. Loprinzi CL. Management of cancer anorexia/cachexia. Support Care Cancer 1995;3:120-122.
36. Kardinal CG, Loprinzi CL, Schaid DJ, Hass AC, Dose AM, Athmann LM, Mailliard JA, McCormack GW, Grestner JB, Schary MF. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 1990;65: 2657-2662.
37. Tisdale MJ. Cancer anorexia and cachexia. Nutrition 2001;17: 438-442.
38. Summerbell CD, Youle M, McDonald V, Catalan J, Gazzard BG. Megestrol acetate vs cyproheptadine in the treatment of weight loss associated with HIV infection. Int J STD AIDS 1992;3:278-280.
39. Homnick DN, Homnick BD, Reeves AJ, Marks JH, Pimentel RS, Bonnema SK. Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatr Pulmonol 2004;38:129-134.
40. Homnick DN, Marks JH, Hare KL, Bonnema SK. Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatr Pulmonol 2005;40:251-256.
41. Calhoun SR, Galloway GP, Smith DE. Abuse potential of dronabinol (marinol®). J Psychoactive Drugs 1998;30:187-195.
42. Ware M, Rueda S, Singer J, Kilby D. Cannabis use by persons living with HIV/AIDS: patterns and prevalence of use. J Cannabis Ther 2003;3:3-15.
43. Braitstein P, Kendall T, Chan K, Wood E, Montaner JSG, O'Shaughnessy M, Hogg RS. Mary-Jane and her patients: sociodemographic and clinical characteristics of HIV-positive individuals using medicinal marijuana and antiretroviral agents. AIDS 2001;15:532-533.
44. Guzman M. Cannabinoids: potential anticancer agents. Nat Rev Cancer 2003;3:745-755.
45. Robson P. Therapeutic aspects of cannabis and cannabinoids. Br J Psychiatry 2001;178:107-115.
46. Beal JE, Olson R, Laubenstein L, Morales JO, Bellman P, Yangco B, Lefkowitz L, Plasse TF, Shepard KV Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995;10:89-97.
47. Beal JE, Olson R, Lefkowitz L, Laubenstein L, Bellman P, Yangco B, Morales JO, Murphy R, Powderly W, Plasse TF, Mosdell KW, Shepard KV Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage 1997;14:7-14.
48. Fride E. Cannabinoids and cystic fibrosis; a novel approach to etiology and therapy. J Cannabis Ther 2002;2:59-71.
49. Anstead MI, Kuhn RJ, Martyn D, Craigmyle L, Kanga JF. Dronabinol, an effective and safe appetite stimulant in cystic fibrosis. Pediatr Pulmonol 2003;36:343.
50. Baptista T, Kin NMKNY, Beaulieu S, de Baptista EA. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 2002;35:205-219.
51. Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand 1999;100: 3-16.
52. Stanton JM. Weight gain associated with neuoleptic medication: a review. Schizophr Bull 1995;21:463-472.
53. Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 2003;28:83-96.
54. Ross E, Davidson S, Sriram S, Hempsey S, Jane Y, Margaret K, Bicknell S. Weight gain associated with low dose olanzapine therapy in severely underweight adults with cystic fibrosis. Pediatr Pulmonol 2005;40:350.
55. Anderson DL, Flume PA, Hardy KK. Psychological functioning of adults with cystic fibrosis. Chest 2001;119:1079-1084.
56. Cowen L, Corey M, Simmons R, Keenan N, Robertson J, Levison H. Growing older with cystic fibrosis: psychologic adjustment of patients more than 16 years old. Psychosom Med 1984;46:363-376.
57. Strauss D, Wellisch D. Psychological assessment of adults with cystic fibrosis. Int J Psychiatry Med 1980;10:265-272.
58. Shepherd SL, Hovell MF, Harwood IR, Granger LE, Hofstetter CR, Molgaard C, Kaplan RM. A comparative study of the psychosocial assets of adults with cystic fibrosis and their healthy peers. Chest 1990;97:1310-1316.
59. Mosie JR, Drotar D, Doershuk CF, Stern RC. Correlates of psychological adjustment among young adults with cystic fibrosis. J Dev Behav Pediartr 1987;8:141-148.
60. Cappelli M, McGrath PJ, Heick CE, MacDonald NE, Feldman W, Rowe P. Chronic disease and its impact. The adolescent's perspective. J Adolesc Health Care 1989;10:283-288.
61. Blair C, Cull A, Freeman C. Psychosocial functioning of young adults with cystic fibrosis and their families. Thorax 1994; 49:798-802.
62. Boyle IR, di Sant' Angese PA, Sack S, Millican F, Kulcycki LL. Emotional adjustment of adolescents and young adults with cystic fibrosis. J Pediatr 1976;88:318-326.
63. Lawler R, Nakielny W, Wright N. Psychological implications of cystic fibrosis. Can Med Assoc J 1966;94:1043-1046.
64. Pearson D, Pumariega A, Seilheimer D. The development of psychiatric sumptomolgy in patients with cystic fibrosis. J Am Acad Child Adolesc Psychiatry 1991;30:290-297.
65. Pumariega AJ, Pursell J, Spock A, Jones JD. Eating disorders in adolescents with cystic fibrosis. J Am Acad Child Psychiatry 1986;25:269-275.
66. Pfeffer PE, Pfeffer JM, Hodson ME. They psychosocial and psychiatric side of cystic fibrosis in adolescents and adults. J Cyst Fibros 2003;2:61-68.
67. Elgudin L, Kishan S, Howe D. Depression in children and adolescents with cystic fibrosis: case studies. Int J Psychiatry Med 2004;34:391-397.
68. Nutt DJ. Tolerability and safety aspects of mirtazapine. Hum Psychopharmacol Clin Exp 2002;17:S37-S41.
69. Boas SR, McColley SA, Danduran MJ, Young J. The role of mirtazapine as an appetite stimulant in malnourished individuals with CF. Ped Pulmonol 2000;30:325.
70. Sykes R, Kittel F, Marcus M, Tarter E, Schroth M. Mirtazapine for appetite stimulation in children with cystic fibrosis. Ped Pulmonol 2006;40:389.
71. Windisch PA, Papatheofanis FJ, Matuszewski KA. Recombinant human growth hormone for AIDS-associated wasting. Ann Pharmacother 1998;32:437-445.
72. Jian Z-M, He G-Z, Zhang S-Y, Wang X-R, Yang N-F, Zhu Y, Wilmore DW. Low-dose growth hormone and hypocaloric nutrition attenuate the protein-catabolic response after major operation. Ann Surg 1989;210:513-525.
73. Medical Economics Company, Inc. Drug topics red book. Montvale, NJ: Medical Economics Company, Inc.; 1998.
74. Seronon Laboratories, Inc. Product information. Serostim (somatropin). Norwell, MA: Seronon Laboratories, Inc.; 1996.
75. Marcus R, Butterfield G, Holloway L, Gilliland L, Baylink DJ, Hintz RL, Sherman BM. Effects on short term administration of recombinant human growth hormone to elderly people. J Clin Endocrinol Metab 1990;70:519-527.
76. Byrand P. The adolescent growth spurt in children with cystic fibrosis. Ann Human Biol 1994;21:229-240.
77. Hardin DS. Growth problems and growth hormone treatment in children with cystic fibrosis. J Pediatr Endocrinol Metabolism 2002;15:731-735.
78. Bechtold S, Ripperger D, Muhlbayer H, Truckenbrodt R, Hafner O, Butenandt O, Schwarz HP. GH therapy in juvenile chronic arthritis: results of a two-year controlled study on growth and bone. J Clin Endocrinol Metab 2002;86:5737-5744.
79. Koch VH, Lippe BM, Sherman BM, Fine RN. Accelerated growth following recombinant human growth hormone therapy in children with chronic renal failure. Pediatr Res 1988;23: 541A.
80. Hardin DS, Ellis KJ, Dyson M, Rice J, McConnell R, Seilheimer DK. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. J Pediatr 2001;139:636-642.
81. Hardin DS, Adams-Huet B, Brown D, Chatfield B, Dyson M, Ferkol T, Howenstine M, Prestidge C, Royce F, Rice J, Seilheimer DK, Steelman J, Shepherds R. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. J Clin Endocrinol Metab 2006;91:4925-4929.
82. Darmaun D, Hayes V Schaeffer D, Welch S, Mauras N. Effects of glutamine and recombinant human growth hormone on protein metabolism in prepubertal children with cystic fibrosis. J Clin Endocrinol Metab 2004;89:1146-1152.
83. Hardin DS, Rice J, Ahn C, Ferkol T, Howenstine M, Spears S, Prestidge C, Seilheimer DK, Shepherd R. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. J Pediatr 2005;146:324-328.
84. Hardin DS, Ferkol T, Ahn C, Dreimane D, Dyson M, Morse M, Prestidge C, Rice J, Seilheimer DK. A retrospective study of growth hormone used in adolescents with cystic fibrosis. Clin Endocrinol 2005;62:560-566.
85. Hardin DS, Rice J, Rosenblatt R. Use of growth hormone in adults with CF. Pediatr Pulmonol 2004;38:343.
86. Schnabel D, Grasemann C, Staab D, Wollmann H, Ratjen F. A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics 2007; e1230-e1238.
87. Orr R, Singh MF. The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders. Drugs 2004;64:725-750.
88. Kuhn CM. Anabolic steroids. Recent Prog Horm Res 2002;57: 411-434.
89. Karim A, Ranney R, Zagarella J, Maibach HI. Oxandrolone disposition and metabolism in man. Clin Pharmacol Ther 1973; 14:862-869.
90. Crock P, Werther GA, Wettenhall HN. Oxandrolone increases final height in turner syndrome. J Paediatr Child Health 1990;26: 221-224.
91. Wilson DM, McCauley E, Brown DR, Dudley R. BioTechnology General Corporation Cooperative Study Group. Oxandrolone therapy in constitutionally delayed growth and puberty. Pediatrics 1995;96:1095-1100.
92. Auerbach HS, Williams M, Kirkpatrick JA, Colten HR. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 1985;2:686-688.
93. Rosenstein BJ, Eigen H. Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics 1991;87:245-246.
94. Eigen H, Rosenstein BJ, FitzSimmons S, Schidlow DV A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic fibrosis foundation prednisone trial group. J Pediatr 1995;126:515-523.
95. Lai HC, Kosorok MR, Allen DB, FizSimmons SC, Rosenstein BJ, Campbell PW, Eigen HH, Farrell PM. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy. Pediatr Pulmonol 1999;28:297.
96. Vaisman N, Clarke R, Rossi M, Goldberg E, Zello GA, Pencharz PB. Protein turnover and resting energy expenditure in patients with undernutrition and chronic lung disease. Am J Clin Nutr 1992;55:63-669.
97. Hardin DS, LeBlanc A, Lukenbaugh S, Para L, Seilheimer DK. Proteolysis associated with insulin resistance in cystic fibrosis. Pediatrics 1998;101:433-437.
98. Harin DS, Ellis K, Dyson M, Rice J, McConnell R, Seilheimer DK. Growth hormone decreases protein catabolism in children with cystic fibrosis. J Clin Endocrinol Metab 2001;86:4424-4428.
99. Serri O, St-Jacques P, Sartippour M, Renier G. Alterations of monocyte function in patients with growth hormone (GH) deficiency: effect of substitutive GH therapy. J Clin Endocrinol Metab 1999;84:58-63.
100. Holt TL, Ward LC, Francis PJ, Isles A, Cooksley WGE, Shepherd RW. Whole body protein turnover in malnourished cystic fibrosis patients and its relationship to pulmonary disease. Am J Clin Nutr 1985;41:1061-1066.
101. Bonefield TL, Panuska JR, Konstan NM. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995; 152:2111-2116.
102. Elborn JS, Cordon SM, Western PJ, MacDonald IA, Shale DJ. Tumour necrosis factor, α, resting energy expenditure and cachexia in cystic fibrosis. Clin Sci 1993;85:563-568.